Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
4.97 (1y: -15%)
Market Cap 274.5 M P/E(ttm) 31.40
Enterprise Value 180.58 M P/B 1.90
SCLN- NAS (USA)
SciClone Pharmaceuticals
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$4.97
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 58.289
SCLN's Cash to Debt is ranked higher than
67% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. SCLN: 58.289 )
SCLN' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: 58.29
Equity to Asset 0.625
SCLN's Equity to Asset is ranked higher than
66% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. SCLN: 0.625 )
SCLN' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.87
Current: 0.63
0.37
0.87
Interest Coverage 66.8
SCLN's Interest Coverage is ranked lower than
94% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. SCLN: 66.8 )
SCLN' s 10-Year Interest Coverage Range
Min: 67   Max: No Debt
Current: 66.8
F-Score: 5
Z-Score: 5.76
M-Score: -4.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 4.10
SCLN's Operating margin (%) is ranked lower than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. SCLN: 4.10 )
SCLN' s 10-Year Operating margin (%) Range
Min: -424.3   Max: 26.3
Current: 4.1
-424.3
26.3
Net-margin (%) 6.2
SCLN's Net-margin (%) is ranked lower than
85% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. SCLN: 6.2 )
SCLN' s 10-Year Net-margin (%) Range
Min: -570.3   Max: 24.8
Current: 6.2
-570.3
24.8
ROE (%) 6.7
SCLN's ROE (%) is ranked lower than
84% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. SCLN: 6.7 )
SCLN' s 10-Year ROE (%) Range
Min: -293.1   Max: 25.6
Current: 6.7
-293.1
25.6
ROA (%) 5.5
SCLN's ROA (%) is ranked lower than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. SCLN: 5.5 )
SCLN' s 10-Year ROA (%) Range
Min: -180.3   Max: 21.6
Current: 5.5
-180.3
21.6
ROC (Joel Greenblatt) (%) 25.50
SCLN's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. SCLN: 25.50 )
SCLN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2242.9   Max: 90.2
Current: 25.5
-2242.9
90.2
Revenue Growth (%) 14.9
SCLN's Revenue Growth (%) is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. SCLN: 14.9 )
SCLN' s 10-Year Revenue Growth (%) Range
Min: -3.5   Max: 21.2
Current: 14.9
-3.5
21.2
EBITDA Growth (%) -11.7
SCLN's EBITDA Growth (%) is ranked lower than
75% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.35 vs. SCLN: -11.7 )
SCLN' s 10-Year EBITDA Growth (%) Range
Min: -25   Max: 10
Current: -11.7
-25
10
EPS Growth (%) -10.6
SCLN's EPS Growth (%) is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. SCLN: -10.6 )
SCLN' s 10-Year EPS Growth (%) Range
Min: -40.1   Max: 88
Current: -10.6
-40.1
88
ยป SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SCLN Guru Trades in Q2 2012

Steven Cohen 16,771 sh (New)
Chuck Royce 11,700 sh (unchged)
Jim Simons 119,029 sh (-74.35%)
» More
Q3 2012

SCLN Guru Trades in Q3 2012

Paul Tudor Jones 96,800 sh (New)
Steven Cohen 25,334 sh (+51.06%)
Chuck Royce 11,700 sh (unchged)
Jim Simons Sold Out
» More
Q4 2012

SCLN Guru Trades in Q4 2012

Jim Simons 20,928 sh (New)
Paul Tudor Jones 103,600 sh (+7.02%)
Chuck Royce 11,700 sh (unchged)
Steven Cohen 15,960 sh (-37%)
» More
Q1 2013

SCLN Guru Trades in Q1 2013

Chuck Royce 11,700 sh (unchged)
Steven Cohen Sold Out
Jim Simons 14,430 sh (-31.05%)
Paul Tudor Jones 63,800 sh (-38.42%)
» More
» Details

Insider Trades

Latest Guru Trades with SCLN



No Insider Trades Found!

Top Ranked Articles about SciClone Pharmaceuticals

Weekly CFO Sells Highlight: V, SCLN, VR, AMSG
June 25, 2012
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Visa Inc., SciClone Pharmaceuticals Inc., Validus Holding Ltd. and Amsurg Corp. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 30.20
SCLN's P/E(ttm) is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.76 vs. SCLN: 30.20 )
SCLN' s 10-Year P/E(ttm) Range
Min: 6.32   Max: 280
Current: 30.2
6.32
280
P/B 1.80
SCLN's P/B is ranked higher than
73% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SCLN: 1.80 )
SCLN' s 10-Year P/B Range
Min: 0.82   Max: 19.09
Current: 1.8
0.82
19.09
P/S 1.80
SCLN's P/S is ranked higher than
60% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. SCLN: 1.80 )
SCLN' s 10-Year P/S Range
Min: 0.67   Max: 39.03
Current: 1.8
0.67
39.03
PFCF 6.60
SCLN's PFCF is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. SCLN: 6.60 )
SCLN' s 10-Year PFCF Range
Min: 3.83   Max: 458
Current: 6.6
3.83
458
EV-to-EBIT 28.6
SCLN's EV-to-EBIT is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. SCLN: 28.6 )
SCLN' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 31.9
Current: 28.6
0.2
31.9
Shiller P/E 29.1
SCLN's Shiller P/E is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.12 vs. SCLN: 29.1 )
SCLN' s 10-Year Shiller P/E Range
Min: 25   Max: 218.5
Current: 29.1
25
218.5

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 4.8
SCLN's Price/Net Cash is ranked higher than
88% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. SCLN: 4.8 )
SCLN' s 10-Year Price/Net Cash Range
Min: 2.1   Max: 16.7
Current: 4.8
2.1
16.7
Price/Net Current Asset Value 7.5
SCLN's Price/Net Current Asset Value is ranked higher than
71% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. SCLN: 7.5 )
SCLN' s 10-Year Price/Net Current Asset Value Range
Min: 2.7   Max: 22.6
Current: 7.5
2.7
22.6
Price/Tangible Book 2.4
SCLN's Price/Tangible Book is ranked higher than
67% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. SCLN: 2.4 )
SCLN' s 10-Year Price/Tangible Book Range
Min: 0.8   Max: 4.9
Current: 2.4
0.8
4.9
Price/DCF (Projected) 0.8
SCLN's Price/DCF (Projected) is ranked higher than
77% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. SCLN: 0.8 )
SCLN' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 3.1
Current: 0.8
0.8
3.1
Price/Median PS Value 0.4
SCLN's Price/Median PS Value is ranked higher than
73% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.70 vs. SCLN: 0.4 )
SCLN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 2.2
Current: 0.4
0.2
2.2
Price/Graham Number 1.6
SCLN's Price/Graham Number is ranked lower than
79% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SCLN: 1.6 )
SCLN' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 5
Current: 1.6
0.9
5
Earnings Yield (Greenblatt) 3.50
SCLN's Earnings Yield (Greenblatt) is ranked higher than
89% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. SCLN: 3.50 )
SCLN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 482.1
Current: 3.5
3.1
482.1
Forward Rate of Return (Yacktman) 3
SCLN's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.82 vs. SCLN: 3 )
SCLN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -21   Max: 4
Current: 3
-21
4

Business Description

SciClone Pharmaceuticals, Inc. was organized in 1990 as a California corporation and reincorporated in Delaware in 2003. The Company is a global specialty pharmaceutical company with a substantial international business, based mainly in the People's Republic of China (China), and with a product portfolio of novel therapies for cancer and infectious diseases. The Company's strategy is to concentrate on international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN, its brand of thymalfasin or thymosin alpha 1 and its primary product, is sold in over 30 countries for the treatment of the hepatitis B virus and the hepatitis C virus, certain cancers and as a vaccine adjuvant. It plans to expand its commercial operations, currently located mainly in China, with the goal of becoming a significant pharmaceutical company in China's rapidly growing pharmaceutical market. Regulation by governmental authorities in the United States, China and other foreign countries is a significant factor in the manufacturing and marketing of its products, as well as in ongoing research and development activities and in pre-clinical and clinical trials and testing related to its products.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:SPJ.Germany
ยป More Articles for SCLN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
SciClone Pharmaceuticals Inc. (SCLN) CEO Friedhelm Blobel buys 10,000 Shares May 26 2009 
SciClone Pharmaceuticals Inc. (SCLN) CFO Gary Titus buys 4,625 Shares May 26 2009 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial